Reslizumab (Cinqair®)

Reslizumab (Cinqair) is covered only as the FDA‑approved add‑on maintenance treatment for adults (≥18) with severe eosinophilic asthma who meet the policy criteria; uses not meeting these criteria are excluded. Key requirements: blood eosinophils ≥400 cells/µL (within 4 weeks), ≥3 months prior controller therapy (ICS plus anti‑IL‑5 or another controller or an ICS/LABA), objective evidence of uncontrolled asthma (e.g., ≥2 steroid‑treated exacerbations or ≥1 hospitalization/ED visit or FEV1<80% or FEV1/FVC<0.80 or worsening with steroid taper), prescriber/consult with an allergist/immunologist/pulmonologist, dosing 3 mg/kg IV q4w, initial approval 6 months, and reauthorization after ≥6 months of Cinqair with continued ICS and documented clinical response (renewals 12 months).

"Documentation that Cinqair is prescribed by or in consultation with an allergist, immunologist, or pulmonologist."